Diabetes Type 2

Diabetes and Obesity: Why Obesity Treatment Should Come First
December 02, 2022

An obesity specialist explains why clinicians should start at the root cause when managing patients with type 2 diabetes and obesity.

How to Build an Obesity Phenotype Step-by-Step, with Andres Acosta, MD, PhD
November 16, 2022

Obesity phenotyping uses a battery of validated tests and procedures to determine the root cause of a patient's disease and then match treatment accordingly.

Obesity Phenotypes Explain What Drives the Disease and How to Target Intervention: Expert Interview
November 15, 2022

Mayo Clinic's Andres Acosta, MD, PhD, details the 4 biologic obesity phenotypes his team has identified and how their use can change weight loss outcomes.

Andres Acosta, MD, Discusses the Challenge of Heterogeneity in Response to Obesity Treatment
November 14, 2022

Acosta, a pioneer in the phenotyping of obesity, says one-third of patients don't respond to treatment and he knows why.

AACE President Discusses New Guideline Recommendations for Cardiorenal Protective Therapy in T2D
November 11, 2022

Use of GLP-1 mimetics and SGLT-2 inhibitors for cardiorenal protection in T2D patients is backed by robust clinical trial evidence, says AACE President Sethu Reddy, MD.

Management of Type 2 Diabetes Complications, Comorbidities Focus of AACE 2022 Guideline Update
November 10, 2022

AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.

Obesity Research Roundup for Primary Care: 5 Studies At-a-Glance from ObesityWeek® 2022
November 10, 2022

Semaglutide yields "amazing" weight loss in adolescents, phenotype-tailored lifestyle approach leads to greater weight loss vs standard methods, and more.

Sotagliflozin Cuts Risk by >50% for Heart Failure Readmission, CV Death in Phase 3 SOLOIST-WHF Trial
November 09, 2022

In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.

Empagliflozin Reduced Risk of Renal Disease Progression, CV Death Across CKD Spectrum in EMPA-KIDNEY
November 07, 2022

Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.

AACE President Sethu Reddy, MD, Highlights Updated 2022 Diabetes Guidelines for Primary Care
November 04, 2022

Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.